Diagnostic accuracy of repeat placental growth factor measurements in women with suspected preeclampsia: A case series study by Duhig, Kate E et al.
Acta Obstet Gynecol Scand. 2020;00:1–9.    |  1wileyonlinelibrary.com/journal/aogs
 
Received: 11 August 2019  |  Revised: 24 January 2020  |  Accepted: 28 January 2020
DOI: 10.1111/aogs.13818  
O R I G I N A L  R E S E A R C H  A R T I C L E
Diagnostic accuracy of repeat placental growth factor 
measurements in women with suspected preeclampsia: A case 
series study
Kate E. Duhig1  |   Louise M. Webster1  |   Andrew Sharp2  |   Carolyn Gill1  |    
Paul T. Seed1  |   Andrew H. Shennan1  |   Jenny E. Myers3  |   Lucy C. Chappell1
© 2020 The Authors. Acta Obstetricia et Gynecologica Scandinavica published by John Wiley & Sons Ltd on behalf of Nordic Federation of Societies of 
Obstetrics and Gynecology (NFOG).
Abbreviations: CI, confidence interval; IQR, interquartile range; PlGF, placental growth factor; sFlt-1, soluble fms-like tyrosine kinase 1; ROC, receiver operating characteristic.
1Department of Women and Children’s 
Health, School of Life Course Sciences, 
King’s College London, London, UK
2Department of Women and Children’s 
Health, University of Liverpool, Liverpool, 
UK
3Division of Developmental Biology and 
Medicine, University of Manchester, 
Manchester, UK
Correspondence
Kate E. Duhig, Department of Women 
and Children’s Health, School of Life 
Course Sciences, King’s College London, 




This research was supported by the National 
Institute for Health Research Professorship 
(Chappell RP-2014-05-019). The views 
expressed in this publication are those of 
the author(s) and not necessarily those of 
the NHS, the National Institute for Health 
Research or the Department of Health.
Abstract
Introduction: Preeclampsia affects about 3% of singleton pregnancies and is character-
ized by placental dysfunction. It is associated with significant maternal and perinatal mor-
bidity and mortality. The diagnosis of preeclampsia remains a challenge, and the clinical 
course can develop for weeks before a diagnosis is confirmed. National guidelines have 
approved placental growth factor (PlGF) testing to rule out suspected preeclampsia, but 
the utility of repeated PlGF measurement is unknown. The aim of this case series analy-
sis was to evaluate the test performance of repeated PlGF sampling in women present-
ing with suspected preeclampsia, and to describe relevant clinical outcomes.
Material and methods: Women who presented to maternity services with suspected 
preeclampsia between 20+0 and 36+6 weeks’ gestation who underwent repeat PlGF 
sampling with a minimum test interval of 7 days were assessed. The outcomes were 
delivery for preeclampsia within 14 days of sampling, the proportion changing PlGF 
categories, and time to delivery.
Results: In total, 289 women with suspected preeclampsia undergoing repeat PlGF sam-
pling were included. PlGF <100 pg/mL had a high sensitivity (87.5%, 95% confidence inter-
val [CI] 67.6%-97.3%) and a negative predictive value (97.7%, 95% CI 93.5%-99.5%) at the 
initial test (receiver operating characteristic [ROC] area 0.79, 95% CI 0.68-0.89). Similar test 
performance was seen for PlGF <100 pg/mL when undertaken as a repeat test (sensitivity 
90.7%, 95% CI 85.2%-95.9%, negative predictive value 92.2%, 95% CI 85.3-96.6%). Overall, 
25.6% of women changed PlGF category between the first and second PlGF tests. For each 
PlGF category, determination of time to delivery was similar for first and second tests.
Conclusions: Repeat PlGF measurement demonstrates high negative predictive 
value for determining preeclampsia requiring delivery in 14 days. Repeat testing 
may be clinically useful to risk stratify women with ongoing symptoms of disease. 
Confirmation of the impact of these findings is required in further studies.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
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1  | INTRODUC TION
Preeclampsia affects 2.8% of singleton pregnancies and is character-
ized by placental dysfunction.1 It is associated with significant ma-
ternal and perinatal morbidity and mortality.2 One in 20 stillbirths 
without a congenital anomaly are attributed to, or associated with 
preeclampsia3 and it is a leading cause of iatrogenic preterm birth.4
The prediction and diagnosis of preeclampsia is an important 
component of antenatal maternity care; however, the diagnosis of 
preeclampsia remains a clinical challenge. Presentation is widely vari-
able, and women with preeclampsia may be asymptomatic, even in the 
presence of severe disease. The clinical disease course can progress 
for weeks before a diagnosis is confirmed. The diagnostic criteria for 
preeclampsia, as defined by the International Society for the Study of 
Hypertension in Pregnancy, relies on the assessment of new-onset hy-
pertension and one or more features of multi-organ disease.5 These 
signs and symptoms may be subject to substantial observer error6 and 
are frequently associated with poor test accuracy.5,7,8
The clinical uncertainty associated with diagnosing preeclampsia 
leads to the extensive use of laboratory investigations, and is fre-
quently associated with admissions to hospital for inpatient mon-
itoring. Advances in our understanding of the pathophysiology of 
preeclampsia have highlighted a role for placentally derived an-
giogenic factors as relevant disease biomarkers.9 Placental growth 
factor (PlGF) is a member of the vascular endothelial growth fac-
tor (VEGF) family, that in pregnancy is expressed predominantly 
in placental tissue, and correlates well with placental function. In 
normal pregnancies, PlGF is synthesized in abundance in the syn-
cytiotrophoblast. Circulating PlGF concentrations rise throughout 
pregnancy until 30 weeks’ gestation, thereafter declining towards 
term. It is thought that placental hypoxia, oxidative stress, the re-
lease of pro-inflammatory cytokines and reduced utero-placental 
blood contributing to endothelial activation in preeclampsia causes a 
release of antiangiogenic factors and a subsequent reduction in ma-
ternal serum PlGF.10 A diagnostic accuracy study published in 2013 
demonstrated that in women presenting with suspected preeclamp-
sia, low circulating maternal PlGF concentrations (<100 pg/mL) had 
high sensitivity (96%; 95% CI 89-99%) and negative predictive value 
(98%; 95% CI 93%-99.5%) for diagnosing preeclampsia requiring 
delivery within 14 days.11 In the PARROT cluster randomized con-
trolled trial, single PlGF measurements were revealed to clinicians 
alongside a clinical management algorithm to be used as a diagnostic 
adjunct in suspected preeclampsia. When compared with standard 
practice, there was a reduction seen in the median time to diagnosis 
of preeclampsia from 4.1 to 1.9 days (time ratio 0.36, 95% CI 0.15-
0.87) with a concurrent reduction in severe maternal adverse out-
comes (5.4-3.8%, adjusted odds ratio 0.32, 95% CI 0.11-0.96).12
Of women who tested “normal” for PlGF (>100 pg/mL) in the 
PARROT trial, 10.9% went on to receive a diagnosis of preeclampsia in 
the pregnancy. In 2016, there was one small study of 100 women pub-
lished which looked at repeated PlGF measurements in women pre-
senting with suspected preeclampsia. This gave only limited descriptive 
outcomes of the participants, and no test performance characteris-
tics.13 In 2019, Zeisler and colleagues published a post hoc analysis of 
participants in the PROGNOSIS study, in which repeated soluble fms-
like tyrosine kinase 1 (sFlt-1)/PlGF measurements were undertaken on 
a weekly basis after initial presentation. This showed that there was 
a significantly larger median increase in sFlt-1/PlGF ratio in women 
who subsequently developed preeclampsia or adverse fetal outcomes 
as compared with those who did not (mean difference 21.22 vs 1.40, 
P < .001). These repeated measurements were taken at fixed timepoints 
in all participants, not specifically in women with an ongoing suspicion 
of preeclampsia. The authors did not report test performance statistics 
for the repeat tests, which would enable confirmation that PlGF-based 
tests retain similar test performance when used sequentially.14
We hypothesise that repeat PlGF sampling has high diagnostic 
accuracy in predicting the need for delivery for preeclampsia within 
14 days. Repeat PlGF testing provides clinically important informa-
tion in women in whom a diagnosis of preeclampsia remains uncer-
tain following an initial test.
The aim of this analysis was to assess repeat sampling in a case 
series of women with suspected preeclampsia, to determine test 
performance of the first and second test for predicting preeclamp-
sia requiring delivery within 14 days (as a marker of clinical disease 
severity) and to describe relevant clinical parameters of patients by 
the repeated test results.
2  | MATERIAL AND METHODS
The data for this case series were obtained from pregnant women 
undergoing repeat PlGF testing from the PELICAN,11 MAPPLE (UK 
centers only),15 MAVIS/Manchester Placenta Clinic,16 PEACHES17 and 
PARROT12 studies, collating samples and data from 11 UK maternity 
units. Participants with repeat samples were included from these co-
horts, which spanned the period from January 2011 to October 2018.
Women were included in this case series if they had two or more 
blood samples taken for PlGF in the index pregnancy for the indi-
cation of suspected preeclampsia. Women with a singleton preg-
nancy had the first blood sample taken at clinical presentation with 
Key message
Repeat placental growth factor measurements demon-
strate high negative predictive value for preeclampsia, and 
can risk stratify women with ongoing symptoms of disease.
K E Y W O R D S
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suspected preeclampsia which included one or more of the follow-
ing signs or symptoms: hypertension, dipstick proteinuria, headache 
with visual disturbances, epigastric pain, and fetal growth restric-
tion between 20+0 and 36+6 weeks’ gestation. Women recruited 
with fetal growth restriction needed to have further signs or symp-
toms that led to clinical suspicion of preeclampsia. PlGF samples 
were repeated if women presented to antenatal services with an 
ongoing clinical suspicion of disease, and all second PlGF samples 
were taken 7 days or more from the first test. Women were ex-
cluded from this analysis if the repeat PlGF measurement was taken 
less than 7 days from the first test. Management decisions were left 
to the treating clinician’s discretion.
Blood samples were taken from women into bottles contain-
ing ethylenediamine tetra-acetic acid, and tested for PlGF con-
centration following centrifugation on a Triage (Alere, now Quidel 
Cardiovascular Inc.) instrument, according to the manufacturer’s 
instructions. The sample results were in some cases revealed to the 
clinical term (in 131 women) and masked in others (in 158 women). 
Anonymized clinical data were collected in all cases in real time. 
Pregnancy outcome data were captured from the electronic patient 
records after birth. Preeclampsia was defined by the International 
Society for the Study of Hypertension in Pregnancy 2014 state-
ment.18 All data were checked for completeness and adjudicated by 
the lead investigators of each study. Missing data from electronic 
records were retrieved from case notes where possible.
2.1 | Statistical analyses
Women were classified according to the gestation of the test (<35 
and 35-36+6 weeks’ gestation).
Women were categorized by their measured PlGF concentration 
into the following predetermined groups:
1. PlGF ≥100 pg/mL—determined as “normal”
2. PlGF 12-99 pg/mL, equivalent to <5th centile for gestation and 
determined as “low”
3. PlGF <12 pg/mL, the lowest limit of detection for the assay and 
determined as “very low”
These categorical groups were used based on the evidence that 
in those presenting <35 weeks’ gestation, “low” PlGF has a high di-
agnostic accuracy (0.96; 95% CI 0.89-0.99) and negative predictive 
value (0.98; 95% CI 0.93-0.995) of determining preeclampsia requir-
ing delivery in 14 days in a prospective observational cohort study,11 
and “very low” PlGF is the lowest limit of detection of the assay. 
We have previously reported that a PlGF threshold of <100 pg/mL 
predicted preeclampsia requiring delivery within 14 days or before 
37 weeks’ gestation (whichever was sooner) with sensitivity and 
negative predictive values similar to diagnostic accuracy estimates 
obtained by using a <5th centile cut-off. The study reflects national 
guidance, which recommends that PlGF is implemented as a rule-out 
test up to 34+ 6 weeks’ gestation.11
For further sub-classification of normal and low values, visual in-
spection of the data was undertaken and clinically applicable thresh-
olds explored.
A positive test was PlGF <100 pg/mL. Test performance for the 
first test, and the repeat test for the primary endpoint of preeclamp-
sia requiring delivery within 14 days (or before 37 weeks’ gestation 
in those recruited between 35+0 and 36+6) was calculated using sen-
sitivity, specificity, positive and negative predictive values, positive 
and negative likelihood ratios, and receiver operating characteristic 
(ROC) areas, all with 95% confidence intervals. Test performance for 
the repeat test following an initial normal (PlGF >100 pmg/mL) test 
was also calculated. Median and interquartile ranges for time from 
second PlGF test to delivery were calculated, stratified by the result 
of the first test. Birthweights are presented as birthweight centiles.19 
An additional sensitivity analysis of the test performance was per-
formed on samples where the results were not revealed to clinicians 
in order to avoid treatment paradox. All statistical analyses were un-
dertaken using STATA version 14.2 (StataCorp, College Station, TX).
2.2 | Ethical approval
Ethical permission was obtained for research studies: PELICAN (East 
London Research Ethics Committee (ref. 10/H0701/117), PEACHES 
(ref. 11/LO/1776), and PARROT (ref. 15/LO/2058), but was not re-
quired for MAPPLE15 or MAVIS,16 as these were service evaluations 
using anonymized data.
3  | RESULTS
In this case series, between January 2011 and October 2018, 289 
women underwent repeated PlGF measurement. Of these, 149 were 
from the PELICAN study, 13 from the MAPPLE study, 58 from the 
MAVIS study, 44 from the PARROT trial and 25 from the PEACHES 
cohort study. Participant characteristics are given in Table 1.
The median test interval between the first and second test was 
15 days (interquartile range [IQR] 10-28 days) and all values, includ-
ing outliers, were included. In those testing with an initial PlGF of 
>100 pg/mL (133 women), the median test interval was 22 days (IQR 
14-38 days). In those testing with an initial PlGF of 12-100 pg/mL 
(125 women), the median test interval was 14 days (IQR 8-22 days). 
In those testing with an initial PlGF of <12 pg/mL (31 women), the 
median test interval was 11 days (IQR 8-14 days). The median gesta-
tion of participants at the first test was 31+0 weeks (IQR 27+1-33+4), 
and at the repeat test was 34+0 weeks (IQR 31+3-36+1). The overall 
median PlGF at the first test was 53.9 pg/mL (IQR 19-262) and the 
median of the repeat PlGF test was 30.6 pg/mL (IQR 12.1-124).
At the initial test, 46.0% (n = 133) of women had a PlGF >100 pg/
mL, 43.3% (n = 125) had a PlGF of 12-100 pg/mL and 10.7% (n = 31) had 
a PlGF of <12 pg/mL. Overall, 25.6% of women changed PlGF category 
between the first and second PlGF tests. In those testing with an initial 
PlGF >100 pg/mL, we determined the chance of changing to a lower 
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category at the second test, based on the level of PlGF at the initial test. 
In women testing with a PlGF 101-199 pg/mL, 75% (12/16) changed 
category at the second test, of those testing 200-499 pg/mL, 31% 
(8/26), changed category, and of those testing >500 pg/mL, 14% (3/23) 
changed category. In those testing initially with a PlGF 12-100 pg/mL, 
those testing 12-19 pg/mL, 41% (8/19) changed to a PlGF <12 pg/mL 
at the second test, whereas those testing 20-100 pg/mL 16% (8/50) 
changed to a PlGF of <12 pg/mL at the second test.
Figure 1 demonstrates the proportion of women changing 
PlGF categories between the first and second tests. There were no 
women who moved from very low PlGF (<12 pg/mL) to normal PlGF 
(>100 pg/mL) at the second test.
The diagnostic accuracy of PlGF (at the prespecified thresh-
old of <100 pg/mL) in predicting preeclampsia requiring delivery 
within 14 days (or <37 weeks’ gestation in those recruited at 35+0 
to 36+6 weeks’ gestation) for the repeat PlGF test was high: sensi-
tivity 90.7% (95% CI 82.5-95.9), negative predictive value 92.2% 
(95% CI 85.3-96.6) and, similar to that of the first PlGF test in this 
cohort: sensitivity 87.5% (95% CI 67.6-97.3), negative predictive 
value 97.7% (95% CI 93.5-99.5). The test performance for the re-
peat PlGF test in women initially testing with a “rule out” PlGF of 
>100 pg/mL gave a sensitivity of 52.9% (95% CI 27.8%-77.0%) and a 
negative predictive value of 91.6% (95% CI 84.1%-96.3%) (Table 2). 
In a sensitivity analysis, similar high test performance was found 








Maternal age, y, mean (SD) 32.1 (6.0) 32.2 (6.2) 31.7 (5.5)
Body mass index, kg/m2, mean (SD) 28.8 (6.4) 28.9 (6.1) 28.7 (7.2)
Ethnicity
White 184 (63.7%) 133 (63.6%) 51 (63.7%)
Black 66 (22.8%) 49 (23.4%) 17 (21.3%)
Asian 22 (7.6%) 14 (6.7%) 8 (10.0%)
Mixed 14 (4.8%) 11 (5.3%) 3 (3.8%)
Other (including Chinese) 3 (1.0%) 2 (1.0%) 1 (1.3%)
Parity
0 144 (50.9%) 123 (58.9%) 21 (28.4%)
1 79 (27.9%) 47 (22.5%) 32 (43.2%)
2 34 (12.0%) 22 (10.5%) 12 (16.2%)
>2 26 (9.2%) 17 (8.1%) 9 (12.2%)
Previous preeclampsia 45 (15.6%) 43 (20.7%) 2 (2.5%)
Chronic hypertension 72 (26.2%) 44 (22.6%) 8 (35.0%)
Chronic kidney disease 25 (9.1%) 16 (8.2%) 9 (11.3%)
Pre-pregnancy diabetes 14 (5.1%) 4 (2.1%) 10 (12.5%)
Booking blood pressure, mm Hg, mean (SD)
Systolic 133 (21) 138 (20) 120 (19)
Diastolic 84 (15) 87 (14) 74 (13)
Gestation at sampling first test, median (IQR) 30+6 (27+0-33+5) 31+0 (32+5-34+2) 29+3 (26+6-32+23)
Gestation at sampling repeat test, median (IQR) 34.0 (31+3-36+0) 34+0 (32+2-36+5) 33+0 (30+1-35+0)
Gestation at delivery, median (IQR) 37+0 (35+0-38+2) 37+0 (35+0-38+2) 37+0 (35+2-37+5)
Preterm delivery <37 wk, n (%) 130 (45.0%) 93 (44.5%) 37 (46.3%)
Small for gestational age (<10th centile)19 80 (38.5%) 56 (26.8%) 29 (36.3%)
Birthweight (g) 2464 (1835, 2929) 2550 (1835, 3120) 2445 (2018, 2770)
Preeclampsia diagnosis, n (%) 143 (55.2%) 128 (61.2%) 31 (38.8%)
Mode of delivery, n (%)
Spontaneous 70 (29.8%) 61 (34.3%) 25 (31.3%)
Assisted 23 (9.8%) 20 (11.2%) 4 (5.0%)
Elective cesarean section 100 (42.6%) 65 (36.5%) 37 (46.3%)
Emergency cesarean section 42 (17.9%) 32 (18.0%) 14 (17.5%)
Abbreviations: IQR, interquartile range; PlGF, placental growth factor.
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when restricting to samples with results masked to clinicians (first 
test: sensitivity 94.1% (95% CI 71.3-99.9), negative predictive value 
98.5% (95% CI 91.7-100), second test: sensitivity 95.7% (95% CI 
85.5%-99.5%), negative predictive value 95.2% (95% CI 82.8%-
99.4%) (Table 3).
Table 3 and Figure 2 present the diagnostic accuracy of the 
first and second PlGF tests in predicting preeclampsia requiring 
delivery within 14 days (or delivery <37 weeks in those recruited 
at 35+0 to 36+6 weeks’ gestation) in those undergoing masked PlGF 
testing (158 women). The ROC area for the repeat test is 0.78 (95% 
CI 0.72-0.84), very similar to that for the first test (0.80, 95% CI 
0.68-0.89).
We investigated using the absolute difference in PlGF concen-
tration, and the ratio of the values, and found that these measures of 
deterioration (eg, differences <0 and ratios <1) gave areas under the 
ROC curve of 0.47 and 0.53, respectively.
Time to delivery in days by the second PlGF result, stratified by 
the initial PlGF sample, is given in Figure 3 (with accompanying val-
ues in Table 4). The time to delivery was similar whether the test was 
on repeat or initial presentation, and trends across the sub-catego-
ries remained similar regardless of initial test category.
4  | DISCUSSION
This case series analysis demonstrates that repeat PlGF testing in 
women with suspected preeclampsia before 37 weeks’ gestation 
maintains a high sensitivity and negative predictive value in de-
termining which women are likely to need delivery for preeclamp-
sia within 14 days. The prevalence of preeclampsia in this study is 
similar to that seen in other prospective cohort studies recruiting 
F I G U R E  1   Proportion of women changing placental growth 













Prevalence of clinically diagnosed 
preeclampsia requiring delivery (%)
8.3 29.8 12.8
Sensitivity (%) 87.5 90.7 52.9
95% CI 67.6-97.3 82.5-95.9 27.8-77.0
n/N 21/24 78/86 9/17
Specificity (%) 59.1 46.8 75.0
95% CI 42.9-55.2 39.8-53.9 66.1-82.6
n/N 130/265 95/203 87/116
Positive predictive value (%) 13.5 41.9 23.7
95% CI 8.5-19.8 34.8-49.4 11.4-40.2
n/N 21/156 78/186 9/38
Negative predictive value (%) 97.7 92.2 91.6
95% CI 93.5-99.5 85.3-96.6 84.1-96.3
n/N 130/133 95/103 87/95
Positive likelihood ratio 1.72 1.70 2.12
95% CI 1.42-2.08 1.47-1.97 1.22-3.66
Negative likelihood ratio 0.25 0.20 0.63
95% CI 0.09-0.74 0.10-0.39 0.37-1.05
ROC area 0.79 0.78 0.65
95% CI 0.68-0.89 0.72-0.84 0.49-0.81
Abbreviations: CI, confidence interval; N, total number; PlGF, placental growth factor; ROC, 
receiver operating characteristic.
TA B L E  2   Test performance statistics 
for low placental growth factor (<100 pg/
mL) in predicting preeclampsia requiring 
delivery within 14 d (or delivery <37 wk 
gestation in those presenting at 35+0 to 
36+6 wk) of sample
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women with suspected preeclampsia.11,16,20 Women in all categories 
of the initial PlGF test change category, demonstrating that PlGF is 
a dynamic biomarker at the time of suspected clinical disease and 
there may be utility in repeated testing beyond the test performed 
at the initial clinical presentation. Nearly one-third of women with 
an initial “normal” PlGF go on to have a subsequent “low” or “very 
low” PlGF at repeat, supporting a case for evaluating clinical ben-
efit in repeating a PlGF sample to further stratify the women who 
remain at risk.
Time to delivery is markedly different for women in different 
initial PlGF categories. This is seen with both the first and second 
tests when considered in isolation. Importantly, when stratifying 
women by their initial PlGF test, time to delivery is markedly dif-
ferent between women who change or remain within their initial 
PlGF category between the first and second tests. This suggests 
that repeat PlGF testing may improve risk stratified management, 
signposting women for appropriate increased surveillance if they 
remain with suspected clinical disease and change to a lower PlGF 
category.
The strengths of this study include the use of multiple centers 
in the UK, encompassing a demographically diverse population. 
This is the largest study (to our knowledge) of repeat PlGF sam-
pling in women presenting with ongoing suspected preeclamp-













Prevalence of clinically diagnosed 
preeclampsia requiring delivery (%)
10.8 29.7 7.7
Sensitivity (%) 94.1 95.7 60.0
95% CI 71.3-99.9 85.5-99.5 14.7-94.7
n/N 16/17 45/47 3/5
Specificity (%) 45.4 36.0 66.7
95% CI 37.0-54.0 27.1-45.7 53.3-78.3
n/N 64/141 40/111 40/60
Positive predictive value (%) 17.2 38.8 13.0
95% CI 10.2-26.4 29.9-48.3 2.8-33.6
n/N 16/93 45/116 3/23
Negative predictive value (%) 98.5 95.2 95.2
95% CI 91.7-100.0 83.8-99.4 83.8-99.4
n/N 64/65 40/42 40/42
Positive likelihood ratio 1.72 1.50 1.80
95% CI 1.42-2.09 1.29-1.74 0.81-4.01
Negative likelihood ratio 0.13 0.12 0.60
95% CI 0.02-0.88 0.03-0.47 0.20-1.78
ROC area 0.80 0.78 0.58
95% CI 0.70-0.90 0.71-0.86 0.23-0.94
Abbreviations: CI, confidence interval; N, total number; PlGF, placental growth factor; ROC, 
receiver operating characteristic.
TA B L E  3   Test performance statistics 
for low placental growth factor (<100 pg/
mL) in predicting preeclampsia requiring 
delivery within 14 d (or delivery <37 wk 
gestation in those presenting at 35+0 to 
36+6 wk) of sample in subset of women 
with masked placental growth factor 
values
F I G U R E  2   Area under receiver operating curve (AUC) for first 
and second test for low placental growth factor (<100 pg/mL) in 
predicting preeclampsia requiring delivery in 14 d from first and 
second tests in subset of women with masked placental growth 
factor values
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repeat PlGF samples for suspected preeclampsia requiring 
delivery within 14 days. This analysis of repeated PlGF measures 
was undertaken in a high-risk population (women with suspected 
preeclampsia) with 30% preeclampsia prevalence. Results can-
not be directly extrapolated to a lower risk population with a 
lower prevalence of preeclampsia, or to use of repeated mea-
sures in a screening capacity (eg, at a fixed time-point in the third 
trimester).
Although other studies have investigated the use of longitu-
dinal sampling of PlGF in pregnancy,21-23 these have focused on 
the prediction of preeclampsia risk with fixed repeat time-point 
sampling.
This  study has some limitations. It is a retrospective analysis of a 
case series of women drawn from several different cohorts. In those 
changing PlGF category at the second test, our analysis is limited by 
small numbers. Some of the variability in PlGF levels may be a func-
tion of normal gestational fluctuations in pregnancy. In this study, 
PlGF results in some cases were masked and in others revealed to 
the clinical team. A previous cohort comparison study has suggested 
that clinician knowledge of PlGF leads to earlier gestation at deliv-
ery when compared with those undergoing masked testing.15 We 
therefore performed a sensitivity analysis of the test performance 
on the masked data only, to mitigate the risk that the outcome of 
preeclampsia requiring delivery within 14 days was influenced by cli-
nician knowledge of revealed PlGF samples. This demonstrated that 
the sensitivity and negative predictive value remained high, albeit 
with slightly wider confidence intervals due to the smaller numbers 
included in the analysis.
Suspected preeclampsia is one of the most common indications 
for women to present to antenatal assessment services. We know 
from previous studies that PlGF outperforms all tests commonly 
used in antenatal triage settings for the diagnosis of preeclampsia 
at the initial clinical presentation.11 The high sensitivity and nega-
tive predictive value of PlGF testing is clinically valuable, as the low 
false-negative rates are reassuring to women and clinicians plan-
ning follow-up and care pathways. However, there is also a group of 
women who are not diagnosed with preeclampsia at the initial clinical 
presentation who go on to develop preeclampsia at a later point in 
F I G U R E  3   Time to delivery for 
preeclampsia (median, interquartile range) 
stratified by first placental growth factor 
(PlGF) concentration. Shading represents 
category at the first test, and line colour 
indicates category at the second test. 
Red indicates very low PlGF (<12 pg/mL), 
orange, low PlGF (12-100 pg/mL) and 
green, normal PlGF (>100 pg/mL)
TA B L E  4   Time to delivery for preeclampsia (median, interquartile range) stratified by first placental growth factor concentration
Category
Time to delivery (median, 
IQR)
Time to delivery (median, 
IQR) Category
Time to delivery 
(median, IQR)
First test First test Second test Second test stratified by first test Second test
PlGF >100 pg/mL 23 (10-35) 32 (14-52) PlGF >100 pg/mL 26 (15-42)
PlGF 12-100 pg/mL 11 (3-21)
PlGF <12 pg/mL 17 (15-19)
PlGF 12-100 pg/mL 9 (4-23) 7 (2-16) PlGF >100 pg/mL 42 (28-55)
PlGF 12-100 pg/mL 9 (4-20)
PlGF <12 pg/mL 7 (3-11)
PlGF <12 pg/mL 7 (2-14) 6 (2-10) PlGF 12-100 pg/mL 12 (5-16)
PlGF <12 pg/mL 6 (1-9)
Abbreviations: IQR, interquartile range; PlGF, placental growth factor.
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pregnancy. Women with the most severe preeclampsia may not ben-
efit from repeat sampling, as they may reach a diagnosis quickly or 
may need medically indicated delivery before a second test is taken. 
Given the heterogeneity in clinical presentations of suspected pre-
eclampsia and the poor diagnostic accuracy of our current methods 
of clinical assessment, these data show that PlGF may be a useful 
diagnostic adjunct in women where there is ongoing diagnostic un-
certainty. Our finding that the high sensitivity and negative predic-
tive value appears to be maintained at repeat sampling, suggests 
that there may be benefit in repeated testing for women in whom 
a diagnosis remains uncertain. The relatively low positive predictive 
value in both initial and repeat testing may lead to over-investigation 
of women, but as this is a cohort at risk of serious maternal and peri-
natal adverse events, this is likely to be acceptable to women and 
clinicians.
The results of the PARROT trial demonstrated no difference 
in perinatal death rates with revealed PlGF testing, in contrast to 
other case series in the literature.15 It may be that in order to pre-
vent avoidable stillbirths, repeated PlGF testing is indicated along-
side ultrasound fetal surveillance as a means of disease monitoring. 
Further work is required to assess the impact of repeat PlGF testing 
on important maternal and perinatal outcomes, to ascertain rates of 
clinical outcomes in those changing categories at the second test, 
and the cost-effectiveness of repeat PlGF testing.
Women testing closer to the threshold values of 12 or 100 pg/
mL at the initial test are more likely to change category at the 
second test. Further work should therefore determine whether 
PlGF should be considered a continuous variable, as with other 
markers such as platelet count or serum creatinine, and whether 
absolute values or gestation referenced centiles could lead to im-
proved risk discrimination beyond the three currently utilized cat-
egories of PlGF level. A prospective study of repeat PlGF sampling 
could also explore the different scenarios in which repeat testing 
may be indicated, for example in all women to play a role in ongo-
ing risk stratification, in those without a definitive diagnosis but 
whom there is an ongoing clinical suspicion of disease, or even 
in those with confirmed preeclampsia for prognosis of pregnancy 
outcome.
5  | CONCLUSION
Suspected preeclampsia is a clinical challenge encountered 
daily by clinicians in maternity triage settings. The diagnostic 
accuracy of detection of preeclampsia requiring delivery within 
14 days remains high with repeat PlGF testing. Repeat testing 
may be clinically useful to risk stratify women presenting sus-
pected preeclampsia if they present with ongoing symptoms of 
disease.
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